Skip to content

MBX Biosciences, Inc. MBX Other operating expenses

Other operating expenses at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$164.13M+196%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$98.75M+21.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$112.33M+40.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$115.1M+36.4%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$3.96M+303%
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s other operating expenses?
MBX Biosciences, Inc. (MBX) reported other operating expenses of $27.27M in Q1 2026.
How has MBX Biosciences, Inc.'s other operating expenses changed year-over-year?
MBX Biosciences, Inc.'s other operating expenses increased by 2.8% year-over-year, from $26.53M to $27.27M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.